Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 109786, 11 pages
http://dx.doi.org/10.1155/2014/109786
Review Article

Targeting the Glutamatergic System to Treat Pathological Gambling: Current Evidence and Future Perspectives

1Institute of Psychiatry and Psychology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy
2Department of Neuroscience and Imaging, “G. d’Annunzio” University, Chieti, Italy

Received 28 February 2014; Accepted 22 May 2014; Published 12 June 2014

Academic Editor: Sophia Achab

Copyright © 2014 Mauro Pettorruso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Hodgins, J. N. Stea, and J. E. Grant, “Gambling disorders,” The Lancet, vol. 378, no. 9806, pp. 1874–1884, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. W. Kalivas, “The glutamate homeostasis hypothesis of addiction,” Nature Reviews Neuroscience, vol. 10, no. 8, pp. 561–572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. Krupitsky, A. A. Rudenko, A. M. Burakov et al., “Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam,” Alcoholism: Clinical and Experimental Research, vol. 31, no. 4, pp. 604–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Rösner, S. Leucht, P. Lehert, and M. Soyka, “Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes,” Journal of Psychopharmacology, vol. 22, no. 1, pp. 11–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Potenza, “The neurobiology of pathological gambling and drug addiction: an overview and new findings,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 363, no. 1507, pp. 3181–3189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. W. Black, D. P. McNeilly, W. J. Burke, M. C. Shaw, and J. Allen, “An open-label trial of acamprosate in the treatment of pathological gambling,” Annals of Clinical Psychiatry, vol. 23, no. 4, pp. 250–256, 2011. View at Google Scholar · View at Scopus
  7. P. N. Dannon, O. Rosenberg, N. Schoenfeld, and M. Kotler, “Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study,” Frontiers in Psychiatry, vol. 2, article 33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pettorruso, G. Martinotti, M. di Nicola et al., “Amantadine in the treatment of pathological gambling: a case report,” Frontiers in Psychiatry, vol. 3, article 102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Thomas, L. Bonanni, F. Gambi, A. Di Iorio, and M. Onofrj, “Pathological gambling in parkinson disease is reduced by amantadine,” Annals of Neurology, vol. 68, no. 3, pp. 400–404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Pettorruso, G. Conte, E. Righino et al., “2876-Glutamatergic strategies in the treatment of pathological gambling: a pilot study,” European Psychiatry, vol. 28, supplement 1, 1 pages, 2013. View at Publisher · View at Google Scholar
  11. J. E. Grant, S. R. Chamberlain, B. L. Odlaug, M. N. Potenza, and S. W. Kim, “Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study,” Psychopharmacology, vol. 212, no. 4, pp. 603–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. M. Pavlovic, “Psychopharmacological treatment of obsessive-compulsive disorder comorbid with body dysmorphic disorder and pathological gambling disorder,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 23, no. 3, pp. E42–E43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zack and C. X. Poulos, “Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity,” Journal of Psychopharmacology, vol. 23, no. 6, pp. 660–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. E. Grant, S. W. Kim, and B. L. Odlaug, “N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study,” Biological Psychiatry, vol. 62, no. 6, pp. 652–657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. E. Grant, B. L. Odlaug, S. R. Chamberlain et al., “A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers,” The Journal of Clinical Psychiatry, vol. 75, no. 1, pp. 39–45, 2014. View at Publisher · View at Google Scholar
  16. P. N. Dannon, K. Lowengrub, Y. Gonopolski, E. Musin, and M. Kotler, “Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study,” Clinical Neuropharmacology, vol. 28, no. 1, pp. 6–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. A. Berlin, A. Braun, D. Simeon et al., “A double-blind, placebo-controlled trial of topiramate for pathological gambling,” World Journal of Biological Psychiatry, vol. 14, no. 2, pp. 121–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Nicolato, M. A. Romano-Silva, H. Correa, J. V. Salgado, and A. L. Teixeira, “Lithium and topiramate association in the treatment of comorbid pathological gambling and bipolar disorder,” The Australian and New Zealand Journal of Psychiatry, vol. 41, no. 7, pp. 628–629, 2007. View at Publisher · View at Google Scholar
  19. R. Dingledine, K. Borges, D. Bowie, and S. F. Traynelis, “The glutamate receptor ion channels,” Pharmacological Reviews, vol. 51, no. 1, pp. 7–61, 1999. View at Google Scholar · View at Scopus
  20. P. J. Conn and J.-P. Pin, “Pharmacology and functions of metabotropic glutamate receptors,” Annual Review of Pharmacology and Toxicology, vol. 37, pp. 205–237, 1997. View at Google Scholar · View at Scopus
  21. P. J. Kenny and A. Markou, “The ups and downs of addiction: role of metabotropic glutamate receptors,” Trends in Pharmacological Sciences, vol. 25, no. 5, pp. 265–272, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. T. M. Tzschentke and W. J. Schmidt, “Glutamatergic mechanisms in addiction,” Molecular Psychiatry, vol. 8, no. 4, pp. 373–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. L. Cornish and P. W. Kalivas, “Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens,” Journal of Addictive Diseases, vol. 20, no. 3, pp. 43–54, 2001. View at Google Scholar · View at Scopus
  24. C. Heidbreder, “Novel pharmacotherapeutic targets for the management of drug addiction,” European Journal of Pharmacology, vol. 526, no. 1-3, pp. 101–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Melis, S. Spiga, and M. Diana, “The dopamine hypothesis of drug addiction: hypodopaminergic state,” International Review of Neurobiology, vol. 63, pp. 101–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. K. C. Berridge and T. E. Robinson, “What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?” Brain Research Reviews, vol. 28, no. 3, pp. 309–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. M. N. Potenza, “How central is dopamine to pathological gambling or gambling disorder?” Frontiers in Behavioral Neuroscience, vol. 7, article 206, 2013. View at Publisher · View at Google Scholar
  28. M. Pettorruso, G. Martinotti, A. Fasano et al., “Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study,” Psychiatry Research, vol. 215, no. 2, pp. 448–452, 2014. View at Publisher · View at Google Scholar
  29. R. J. van Holst, W. van den Brink, D. J. Veltman, and A. E. Goudriaan, “Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling,” Neuroscience and Biobehavioral Reviews, vol. 34, no. 1, pp. 87–107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. K. McFarland, C. C. Lapish, and P. W. Kalivas, “Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior,” Journal of Neuroscience, vol. 23, no. 8, pp. 3531–3537, 2003. View at Google Scholar · View at Scopus
  31. R. T. LaLumiere and P. W. Kalivas, “Glutamate release in the nucleus accumbens core is necessary for heroin seeking,” Journal of Neuroscience, vol. 28, no. 12, pp. 3170–3177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. K. McFarland and P. W. Kalivas, “The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior,” Journal of Neuroscience, vol. 21, no. 21, pp. 8655–8663, 2001. View at Google Scholar · View at Scopus
  33. C. Nordin, R. C. Gupta, and I. Sjödin, “Cerebrospinal fluid amino acids in pathological gamblers and healthy controls,” Neuropsychobiology, vol. 56, no. 2-3, pp. 152–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. W. Kalivas and N. D. Volkow, “New medications for drug addiction hiding in glutamatergic neuroplasticity,” Molecular Psychiatry, vol. 16, no. 10, pp. 974–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. F. Olive, R. M. Cleva, P. W. Kalivas, and R. J. Malcolm, “Glutamatergic medications for the treatment of drug and behavioral addictions,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 801–810, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Machado-Vieira, L. Ibrahim, I. D. Henter, and C. A. Zarate Jr., “Novel glutamatergic agents for major depressive disorder and bipolar disorder,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 678–687, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. M. di Nicola et al., “Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment,” Journal of Affective Disorders. In press.
  38. D. A. Baker, K. McFarland, R. W. Lake et al., “Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse,” Nature Neuroscience, vol. 6, no. 7, pp. 743–749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. M. Moran, K. McFarland, R. I. Melendez, P. W. Kalivas, and J. K. Seamans, “Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking,” Journal of Neuroscience, vol. 25, no. 27, pp. 6389–6393, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. D. A. Baker, K. McFarland, R. W. Lake, H. Shen, S. Toda, and P. W. Kalivas, “N-acetyl cysteine-induced blockade of cocaine-induced reinstatement,” Annals of the New York Academy of Sciences, vol. 1003, pp. 349–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. M. Kupchik, K. Moussawi, X.-C. Tang et al., “The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine,” Biological Psychiatry, vol. 71, no. 11, pp. 978–986, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. P. W. Kalivas and C. O'Brien, “Drug addiction as a pathology of staged neuroplasticity,” Neuropsychopharmacology, vol. 33, no. 1, pp. 166–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Sani, G. Serra, G. D. Kotzalidis et al., “The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence,” CNS Drugs, vol. 26, no. 8, pp. 663–690, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Van Wageningen, H. A. Jørgensen, K. Specht, and K. Hugdahl, “A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine,” Cerebral Cortex, vol. 20, no. 4, pp. 798–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. R. F. Leeman and M. N. Potenza, “Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity,” Psychopharmacology, vol. 219, no. 2, pp. 469–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Fasano, L. Ricciardi, M. Pettorruso, and A. R. Bentivoglio, “Management of punding in Parkinson's disease: an open-label prospective study,” Journal of Neurology, vol. 258, no. 4, pp. 656–660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Seppi, D. Weintraub, M. Coelho et al., “The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease,” Movement Disorders, vol. 26, no. 3, pp. S42–S80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Weintraub, M. Sohr, M. N. Potenza et al., “Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study,” Annals of Neurology, vol. 68, no. 6, pp. 963–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. T. Gass and M. F. Olive, “Glutamatergic substrates of drug addiction and alcoholism,” Biochemical Pharmacology, vol. 75, no. 1, pp. 218–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. P. De Witte, J. Littleton, P. Parot, and G. Koob, “Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action,” CNS Drugs, vol. 19, no. 6, pp. 517–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Rammes, B. Mahal, J. Putzke et al., “The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801,” Neuropharmacology, vol. 40, no. 6, pp. 749–760, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Spanagel, V. Vengeliene, B. Jandeleit et al., “Acamprosate produces its anti-relapse effects via calcium,” Neuropsychopharmacology, vol. 39, no. 4, pp. 783–791, 2014. View at Publisher · View at Google Scholar
  53. F. Kiefer and K. Mann, “Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy,” Current Pharmaceutical Design, vol. 16, no. 19, pp. 2098–2102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. A. Boothby and P. L. Doering, “Acamprosate for the treatment of alcohol dependence,” Clinical Therapeutics, vol. 27, no. 6, pp. 695–714, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. P. Raj, “Gambling on acamprosate: a case report,” Journal of Clinical Psychiatry, vol. 71, no. 9, pp. 1245–1246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. R. Chalifoux and A. G. Carter, “GABAB receptor modulation of synaptic function,” Current Opinion in Neurobiology, vol. 21, no. 2, pp. 339–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Addolorato, L. Leggio, S. Cardone, A. Ferrulli, and G. Gasbarrini, “Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives,” Alcohol, vol. 43, no. 7, pp. 559–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. F. A. Furieri and E. M. Nakamura-Palacios, “Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 68, no. 11, pp. 1691–1700, 2007. View at Google Scholar · View at Scopus
  59. G. Martinotti, “Pregabalin in clinical psychiatry and addiction: pros and cons,” Expert Opinion on Investigational Drugs, vol. 21, no. 9, pp. 1243–1245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Cuomo, G. D. Kotzalidis, F. Caccia, E. Danese, G. Manfredi, and P. Girardi, “Citalopram-associated gambling: a case report,” Journal of Gambling Studies, vol. 30, no. 2, pp. 467–473, 2014. View at Publisher · View at Google Scholar
  61. J. S. Ballon and D. Feifel, “A systematic review of modafinil: potential clinical uses and mechanisms of action,” Journal of Clinical Psychiatry, vol. 67, no. 4, pp. 554–566, 2006. View at Google Scholar · View at Scopus
  62. J. Martínez-Raga, C. Knecht, and S. Cepeda, “Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies,” Current drug abuse reviews, vol. 1, no. 2, pp. 213–221, 2008. View at Google Scholar · View at Scopus
  63. N. D. Volkow, J. S. Fowler, J. Logan et al., “Effects of modafinil on dopamine and dopamine transporters in the male human brain clinical implications,” Journal of the American Medical Association, vol. 301, no. 11, pp. 1148–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Ferraro, T. Antonelli, W. T. O'Connor, S. Tanganelli, F. Rambert, and K. Fuxe, “The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus,” NeuroReport, vol. 8, no. 13, pp. 2883–2887, 1997. View at Google Scholar · View at Scopus
  65. K. Smart, R. C. Desmond, C. X. Poulos, and M. Zack, “Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers,” Neuropharmacology, vol. 73, pp. 66–74, 2013. View at Publisher · View at Google Scholar
  66. N. Tarrant, A. E. Cavanna, and H. Rickards, “Pathological gambling associated with modafinil,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 1, pp. E27–E28, 2010. View at Google Scholar · View at Scopus
  67. R. Ladouceur, C. Sylvain, C. Boutin, S. Lachance, C. Doucet, and J. Leblond, “Group therapy for pathological gamblers: a cognitive approach,” Behaviour Research and Therapy, vol. 41, no. 5, pp. 587–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. J. E. Grant, S. W. Kim, E. Hollander, and M. N. Potenza, “Predicting response to opiate antagonists and placebo in the treatment of pathological gambling,” Psychopharmacology, vol. 200, no. 4, pp. 521–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Tanaka, K. Watase, T. Manabe et al., “Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1,” Science, vol. 276, no. 5319, pp. 1699–1702, 1997. View at Publisher · View at Google Scholar
  70. Y. Sari, M. Sakai, J. M. Weedman, G. V. Rebec, and R. L. Bell, “Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats,” Alcohol and Alcoholism, vol. 46, no. 3, Article ID agr023, pp. 239–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Jeanblanc, F. Coune, B. Botia, and M. Naassila, “Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine,” Addiction Biology, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Angelucci, V. Ricci, F. Gelfo et al., “BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure,” Brain and Cognition, vol. 84, no. 1, pp. 118–122, 2014. View at Publisher · View at Google Scholar
  73. F. Angelucci, G. Martinotti, F. Gelfo et al., “Enhanced BDNF serum levels in patients with severe pathological gambling,” Addiction Biology, vol. 18, no. 4, pp. 749–751, 2013. View at Publisher · View at Google Scholar · View at Scopus